OXIS introduces ErgoFlex for relief of joint pain

OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS.  ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health.

More than 60 million Americans suffer from joint pain and are increasingly turning to natural cures to improve the health of their joints. Each easy-to-swallow ErgoFlex capsule is loaded with natural nutraceutical ingredients that have been traditionally used to maintain joint health and treat joint pain. Included in the patent-pending formula are turmeric, cat's claw, acai and white willow bark, as well as modern breakthroughs such as Ergothioneine, hyaluronic acid, type II collagen and glucosamine.  One capsule twice a day with meals provides support for the body's continuing battle against inflammation, and also supports the body's natural processes to repair damaged tissue and maintain joint lubrication.

ErgoFlex initially is being marketed through a highly targeted direct mail campaign, a channel with proven success for generating sales of dietary supplements.  OXIS plans to add other direct-to-consumer channels such as Internet sales, radio and television infomercials and multi-level marketing as ErgoFlex and future products under the OXIS ERGO brand are established and demand grows. ErgoFlex is available in 60-capsule containers at a retail price of $39.95.  Additional information, including ordering information, is available at www.helpyourjointsnow.com.

"We are delighted and proud to launch ErgoFlex, our first ERGO-based product and an important entrant in the multi-billion dollar U.S. market for non-prescription joint health products," said Bernie Landes, President of OXIS International.  "This innovative, new product harnesses the power of a proprietary breakthrough antioxidant and is ideally suited for the tens of millions of Americans who suffer with joint pain.  While most joint pain products only address the symptoms, ErgoFlex targets and relieves oxidative stress, which oftentimes is the underlying cause of joint ailments. It also provides a suite of extensively researched natural ingredients that help maintain the structural integrity of joints and relieve pain."

OXIS is supporting the ErgoFlex marketing program with a pilot clinical study evaluating the benefits of the unique ErgoFlex formula for joint pain, inflammation and range of motion.  The study is nearing completion, and involves subjects with mild-to-moderate joint pain who were not previously receiving any medication or treatment for this ailment.  Study participants are taking two capsules of ErgoFlex each day for six weeks, and will be followed for a further six weeks after they stop taking ErgoFlex.

The Company also has undertaken a series of safety and toxicology studies on ERGO to further support the substantial body of existing data. These studies support the preparation of a Generally Recognized as Safe (GRAS) Self Affirmation dossier, which will be reviewed by an expert panel organized and coordinated by AIBMR Life Sciences, a leading natural products scientific consultancy.

Mr. Landes added, "Over the coming months we plan to introduce a number of ERGO-based products that address key health goals of not only an aging population of baby boomers, but also a younger audience seeking to maintain their youthful good health.  These proprietary formulas are directed at optimizing mitochondrial function and overall energy, supporting brain health and maintaining normal vision.  As the sole-source provider of commercial Ergothioneine, OXIS is well-positioned to be a leading participant in the nutraceutical and cosmeceutical industry.  Our strategy includes developing proprietary foods, beverages, lotions and creams, as well as engaging joint venture partners and licensees for additional products and markets."


OXIS International, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Neuropsychiatric symptoms in children and adolescents with long COVID